Mon panier

Human HVEM / TNFRSF14 Protein, His Tag (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
HVM-H52E9-100ug
$330.00
HVM-H52E9-1mg (500ug X 2)
$2040.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    TNFRSF14, ATAR, HVEA, HVEM, LIGHTR, TR2, CD270

  • Source

    Human HVEM, His Tag (HVM-H52E9) is expressed from human 293 cells (HEK293). It contains AA Leu 39 - Val 202 (Accession # Q92956-1).

    Predicted N-terminus: Leu 39

    Request for sequence
  • Molecular Characterization

    HVEM Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 19.2 kDa. The protein migrates as 30-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    HVEM SDS-PAGE

    Human HVEM, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • SEC-MALS

    HVEM SEC-MALS

    The purity of Human HVEM, His Tag (Cat. No. HVM-H52E9) is more than 90% and the molecular weight of this protein is around 30-40 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     HVEM ELISA

    Immobilized Human HVEM, His Tag (Cat. No. HVM-H52E9) at 5 μg/mL (100 μL/well) can bind Human BTLA, Fc Tag (Cat. No. BTA-H5256) with a linear range of 0.01-0.313 μg/mL (QC tested).

    Protocol
  •  HVEM ELISA

    Immobilized Human LIGHT, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. LIT-H5256) at 2 μg/mL (100 μL/well) can bind Human HVEM, His Tag (Cat. No. HVM-H52E9) with a linear range of 0.01-0.156 μg/mL (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Herpesvirus entry mediator (HVEM) is also known as TNFRSF14, TR2 (TNF receptorlike molecule) and ATAR (another TRAF associated receptor), is a type I membrane protein belonging to the TNF/NGF receptor superfamily. HVEM expression has been detected in peripheral blood T cells, B cells, monocytes and in various tissues enriched in lymphoid cells. The extracellular domain of HVEM has been shown to interact directly with the herpes simplex virus envelope glycoprotein D (gD). Two TNF superfamily ligands, including the secreted TNFβ (lymphotoxin α) and the membrane protein LIGHT (lymphotoxins, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes), have been shown to be the cellular ligands for HVEM. Besides HVEM, LIGHT can also interact with LTβR, the receptor for lymphotoxin αβ heterotrimer. The role of the HVEM LIGHT /LTβ receptor ligand pair in immune function and herpesvirus pathobiology remains to be elucidated.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Tumor necrosis factor receptor superfamily member 14

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    0 Détails

  • Étape de développement la plus élevée:

    Preclinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte